Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Issa F Khouri

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 6, 2004
Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findingsJun Gu, Yang O Huh, Feng Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphomaIssa F Khouri, Ming-S Lee, Rima M Saliba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2017
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid MalignanciesIssa F Khouri, Irina Fernandez Curbelo, Francesco Turturro, et al.
Blood|July 27, 2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemiaPartow Kebriaei, Michelle A Detry, Sergio Giralt, et al.
Experimental Hematology|January 17, 2004
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survivalIssa F Khouri, Ming-Sheng Lee, Rima M Saliba, et al.
Annals of Diagnostic Pathology|September 19, 2006
Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantationMalisha R Johnson, Daniel Del Carpio-Jayo, Pei Lin, et al.
Leukemia & Lymphoma|June 11, 2014
Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysisMichelle L Poon, Patricia S Fox, Barry I Samuels, et al.
Transfusion|September 28, 2006
Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesisMartin Körbling, James M Reuben, Hui Gao, et al.
Blood|August 23, 2014
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHDIssa F Khouri, Wei Wei, Martin Korbling, et al.
Leukemia & Lymphoma|August 23, 2006
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphomaChitra Hosing, Rima M Saliba, Martin Körbling, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 6, 2004
Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findingsJun Gu, Yang O Huh, Feng Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphomaIssa F Khouri, Ming-S Lee, Rima M Saliba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2017
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid MalignanciesIssa F Khouri, Irina Fernandez Curbelo, Francesco Turturro, et al.
Blood|July 27, 2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemiaPartow Kebriaei, Michelle A Detry, Sergio Giralt, et al.
Experimental Hematology|January 17, 2004
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survivalIssa F Khouri, Ming-Sheng Lee, Rima M Saliba, et al.
Annals of Diagnostic Pathology|September 19, 2006
Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantationMalisha R Johnson, Daniel Del Carpio-Jayo, Pei Lin, et al.
Leukemia & Lymphoma|June 11, 2014
Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysisMichelle L Poon, Patricia S Fox, Barry I Samuels, et al.
Transfusion|September 28, 2006
Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesisMartin Körbling, James M Reuben, Hui Gao, et al.
Blood|August 23, 2014
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHDIssa F Khouri, Wei Wei, Martin Korbling, et al.
Leukemia & Lymphoma|August 23, 2006
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphomaChitra Hosing, Rima M Saliba, Martin Körbling, et al.
Pageof 7